排序方式: 共有4条查询结果,搜索用时 0 毫秒
1
1.
Sturkenboom H. N. van Hattem V. A. E. Nieuwland W. Paris F. M. A. Magro M. Anthonio R. L. Algin A. Lipsic E. Bruwiere E. Van den Branden B. J. L. Polad J. Tonino P. Tio R. A. 《Netherlands heart journal》2022,30(2):96-105
Netherlands Heart Journal - The current study aimed to evaluate changes in treatment delay and outcome for ST-segment elevation myocardial infarction (STEMI) in the Netherlands during the first... 相似文献
2.
Jan A. Krikken Ad F. M. van den Heuvel H. Marco Willemsen Adriaan A. Voors Erik Lipsic 《Netherlands heart journal》2022,30(9):393
Despite the high prevalence and adverse clinical outcomes of severe tricuspid regurgitation (TR), conventional treatment options, surgical or pharmacological, are limited. Surgery is associated with a high peri-operative risk and medical treatment has not clearly resulted in clinical improvements. Therefore, there is a high unmet need to reduce morbidity and mortality in patients with severe TR. During recent years, several transcatheter solutions have been studied. This review focuses on the transcatheter edge-to-edge repair of TR (TTVR) with respect to patient selection, the procedure, pre- and peri-procedural echocardiographic assessments and clinical outcomes. Furthermore, we highlight the current status of TTVR in the Netherlands and provide data from our initial experience at the University Medical Centre Groningen. 相似文献
3.
Ruben N. Eppinga Minke H. T. Hartman Dirk J. van Veldhuisen Chris P. H. Lexis Margery A. Connelly Erik Lipsic Iwan C. C. van der Horst Pim van der Harst Robin P. F. Dullaart 《PloS one》2016,11(1)
Objective
Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown. We determined whether metformin administration affects lipoprotein subfractions 4 months after ST-segment elevation MI (STEMI). Second, we assessed associations of lipoprotein subfractions with left ventricular ejection fraction (LVEF) and infarct size 4 months after STEMI.Methods
371 participants without known diabetes participating in the GIPS-III trial, a placebo controlled, double-blind randomized trial studying the effect of metformin (500 mg bid) during 4 months after primary percutaneous coronary intervention for STEMI were included of whom 317 completed follow-up (clinicaltrial.gov Identifier: ). Lipoprotein subfractions were measured using nuclear magnetic resonance spectroscopy at presentation, 24 hours and 4 months after STEMI. (Apo)lipoprotein measures were obtained during acute STEMI and 4 months post-STEMI. LVEF and infarct size were measured by cardiac magnetic resonance imaging. NCT01217307Results
Metformin treatment slightly decreased LDL cholesterol levels (adjusted P = 0.01), whereas apoB remained unchanged. Large LDL particles and LDL size were also decreased after metformin treatment (adjusted P<0.001). After adjustment for covariates, increased small HDL particles at 24 hours after STEMI predicted higher LVEF (P = 0.005). In addition, increased medium-sized VLDL particles at the same time point predicted a smaller infarct size (P<0.001).Conclusion
LDL cholesterol and large LDL particles were decreased during 4 months treatment with metformin started early after MI. Higher small HDL and medium VLDL particle concentrations are associated with favorable LVEF and infarct size. 相似文献4.
Timmermans Marijke J. C. Houterman Saskia Daeter Edgar D. Danse Peter W. Li Wilson W. Lipsic Erik Roefs Maaike M. van Veghel Dennis 《Netherlands heart journal》2022,30(12):546-556
Netherlands Heart Journal - Worldwide, quality registries for cardiovascular diseases enable the use of real-world data to monitor and improve the quality of cardiac care. In the Netherlands Heart... 相似文献
1